Nasdaq12d
Validea Detailed Fundamental Analysis - SRPT
Below is Validea's guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our P/B Growth Investor model based on the published ...
Nasdaq4d
Sarepta Therapeutics Breaks Above 200-Day Moving Average - Bullish for SRPT
In trading on Tuesday, shares of Sarepta Therapeutics Inc (Symbol: SRPT) crossed above their 200 day moving average of $129.96, changing hands as high as $131.00 per share. Sarepta Therapeutics ...
Nasdaq3d
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet
Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short ...
Nasdaq5d
Analyst Expectations For Sarepta Therapeutics's Future
14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...
Nasdaq10d
HC Wainwright & Co. Initiates Coverage of Sarepta Therapeutics (SRPT) with Sell Recommendation
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation. As of November 21, 2024, the average one-year ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Commerce Bank
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
Arrowhead climbs after licensing deal with Sarepta
Arrowhead Pharmaceuticals (ARWR) stock surges 21% in premarket after $825M licensing deal with Sarepta (SRPT) for rare ...
Nasdaq4d
Sarepta deal with Arrowhead a ‘prudent move,’ says Leerink
After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets for rare genetic diseases, Leerink analyst Joseph ...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...
Nasdaq4d
Sarepta price target raised to $217 from $210 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Sarepta (SRPT) to $217 from $210 and keeps a Buy rating on the shares after the company announced an agreement with Arrowhead (ARWR ...
Nasdaq4d
Sarepta Therapeutics Announces Leadership Change and Equity Deal
An announcement from Sarepta Therapeutics ( (SRPT)) is now available. Sarepta Therapeutics is undergoing a leadership change as Ryan Brown steps down, with Cristin Rothfuss set to succeed him.